NCT00869752 - MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2009

Primary Completion Date

March 15, 2012

Study Completion Date

July 4, 2012

Conditions

Lung Cancer

Interventions

BIOLOGICAL

anti-IGF-1R recombinant monoclonal antibody MK-0646

MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days

DRUG

cisplatin

MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days

DRUG

etoposide

MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days

Trial Locations (3)

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto